PHILADELPHIA, PA — Context Therapeutics Inc. has confirmed its presence at several prominent investor conferences scheduled over the coming months. The company will update investors on its innovative pipeline, including its flagship therapeutic programs, and engage in one-on-one meetings with key stakeholders across the healthcare and investment sectors.
Investor Conference Schedule
The lineup of conferences includes a mix of in-person and virtual events known for their focus on healthcare innovation:
- Stifel Virtual Targeted Oncology Forum (April 8-9, 2025)
- Presentation: April 8, 10:00 AM ET
- One-on-one meetings available on April 8-9
- Jones Healthcare and Technology Innovation Conference (Las Vegas, April 8-9, 2025)
- One-on-one meetings exclusively on April 9
- 24th Annual Needham Virtual Healthcare Conference (April 7-10, 2025)
- One-on-one meetings on April 8
- Citizens Life Sciences Conference (New York City, May 7-8, 2025)
- Presentation: May 8, 2:30 PM ET
- One-on-one meetings on May 8
These events enable Context Therapeutics to showcase its progress and engage with potential partners, investors, and other stakeholders in the biotechnology and pharmaceutical industries.
Advancing T Cell Engaging Bispecific Antibodies
Context Therapeutics has earned recognition for its commitment to developing cutting-edge antibody-based therapies for solid tumors. The company’s portfolio includes TCE bispecific therapeutics designed to target key tumor-associated proteins and direct T cells to eliminate cancer cells effectively.
Its lead programs include:
- CTIM-76 – A Claudin 6 x CD3 TCE targeting Claudin 6, a tumor-specific protein expressed in various cancers.
- CT-95 – A Mesothelin x CD3 TCE designed to target tumors overexpressing mesothelin, such as ovarian and pancreatic cancers.
- CT-202 – A Nectin-4 x CD3 TCE aimed at addressing cancers that present Nectin-4, including bladder and breast cancers.
These programs are part of a broader effort by Context to redefine the therapeutic approach to solid tumors by leveraging the precision of TCEs. By engaging the immune system more effectively, these therapies hold promise for improving patient outcomes in conditions with limited treatment options.
Context Therapeutics
Headquartered in Philadelphia, Context Therapeutics is at the forefront of oncology innovation, aiming to combat a range of solid tumors using its proprietary TCE bispecific platform. With a deep focus on research and development, the company is committed to transforming the treatment landscape for cancer patients worldwide.
For Context and its investors, these conferences come at a critical junction as the company continues to build momentum and demonstrate the potential of its TCE platform to address some of the toughest challenges in oncology.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.